Is Clearmind Medicine Inc. (CMND) Halal?
Shariah Screening — 5 Standards
Based on financial data from October 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 86.9% / 30% | 273.0% / 30% | 15.8% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 86.9% / 33% | 273.0% / 33% | 15.8% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 29.2% / 33% | 91.8% / 33% | 5.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 86.9% / 33% | 273.0% / 33% | 15.8% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 29.2% / 33% | 91.8% / 33% | 5.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -119.7% | |
| Return on Assets (ROA) | -55.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$5M |
| Free Cash Flow | -$5M |
| Total Debt | $2M |
| Debt-to-Equity | 0.1 |
| Current Ratio | 3.8 |
| Total Assets | $6M |
Price & Trading
| Last Close | $0.74 |
| 50-Day MA | $1.42 |
| 200-Day MA | $22.15 |
| Avg Volume | 258K |
| Beta | -1.1 |
|
52-Week Range
$0.59
| |
About Clearmind Medicine Inc. (CMND)
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post-traumatic stress disorder and other health conditions; Polyrizon Ltd. to develop novel intranasal MEAI formulation; and NeuroThera Labs Inc. to develop a therapy for weight loss and Metabolic Dysfunction-Associated Steatotic Liver Disease. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Clearmind Medicine Inc. (CMND) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Clearmind Medicine Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Clearmind Medicine Inc.'s debt ratio?
Clearmind Medicine Inc.'s debt ratio is 86.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 29.2%.
What are Clearmind Medicine Inc.'s key financial metrics?
Clearmind Medicine Inc. has a market capitalization of $2M. Return on equity stands at -119.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.